PanTheryx Medical Pvt. Ltd.
1800 30th St.
13 articles with PanTheryx Medical Pvt. Ltd.
PanTheryx, the world’s largest colostrum-based nutrition and biotechnology company, announced today it has closed on the purchase of the Goodgut® digestive health brands, including its Preliva® polyphenol prebiotic formula. Goodgut’s plant-based Preliva is designed to help the natural bacteria in the gut flourish which supports the body
PanTheryx, the world’s largest colostrum-based nutrition and biotechnology company, announced today the appointment of Tom Feeley to the position of Chief Financial Officer (CFO). Mr. Feeley began his role with PanTheryx on June 22 and reports to President and Chief Executive Officer Wes Parris. Mr. Feeley will be responsible for the development and execution of PanTheryx’s financial strategy including all Finance, Account
Liepmann and Erickson add invaluable industry expertise to the Board with more than 60 combined years of nutrition and food science experience
PanTheryx announced today that CEO Mark Braman is retiring and nutrition industry veteran, Wes Parris, formerly of I-Health, Inc., will replace Braman as CEO effective immediately.
Independent expert panel recognizes gut and immune supporting ingredient from leading biotechnology company as Generally Recognized as Safe (GRAS)
PanTheryx Announces Exclusive Multimillion Dollar Agreement between APS BioGroup and VitaDairy in Pediatric and Maternal Immunonutrition
World leader in bovine colostrum manufacturing and research launches new deal with Vietnamese nutritional dairy company, becoming the exclusive colostrum supplier for its immunonutrition products
PanTheryx, a biotechnology company, today announced that it has appointed Dr. Mehmet C. Oz, MD, surgeon and talk show host “Dr. Oz” from The Dr. Oz Show, to the company’s board of directors.
Company launches new efforts through its Equity of Access Initiative to reduce the burden of pediatric infectious diarrhea on the poorest and hardest to reach children in Cambodia.
PanTheryx partners with Zuellig Pharma to launch DiaResQ in Cambodia.
PanTheryx Announces $50 Million Financing, Accelerates Development of its Novel Biologics and Medical Foods Candidates
PanTheryx, a biotechnology company focused on addressing serious GI related health conditions, announced today that it has completed $50 million in new financing with Perceptive Advisors.
Rajiv Shah and Tom Bumol Join PanTheryx Board of Directors as Biotech Expands Pipeline Candidates with Substantial R&D Investment
PanTheryx, a biotechnology company focused on addressing serious GI related health conditions, announced today the appointment of Dr. Rajiv Shah, MD, president of the Rockefeller Foundation, and Dr. Tom Bumol, PhD, executive director of the Allen Institute for Immunology, to its board of directors.
PanTheryx Presents Positive Results from Two New DiaResQ Studies at its 2019 International Scientific Symposium
New clinical data and case studies highlight the use of DiaResQ in a range of real world settings, from hospitals to disaster relief, in its first annual scientific meeting